Insulin detemir for the treatment of obese patients with type 2 diabetes
Priscilla A Hollander1,21Baylor Endocrine Center, 2Baylor Medical Center, Dallas, Texas, USAAbstract: The risk for developing type 2 diabetes (T2DM) is greater among obese individuals. Following onset of the disease, patients with T2DM become more likely to be afflicted with diabetic micro- and macr...
Guardado en:
Autor principal: | Hollander PA |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7f4d03e329264a229836c8e3fbe450cd |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Analog insulin detemir for patients with type 1 and type 2 diabetes: a review
por: Gregory E Peterson
Publicado: (2009) -
Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics
por: Jean-Pierre Le Floch
Publicado: (2010) -
Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
por: Stanley S Schwartz
Publicado: (2010) -
Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring
por: Abe S, et al.
Publicado: (2011) -
Management of obesity, insulin resistance and type 2 diabetes in children: consensus and controversy
por: Amy Fleischman, et al.
Publicado: (2009)